A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with advanced/metastatic pancreatic cancer, and determine the RP2D for SHR-1701 in the combined regimen.

Timeline

Start

2020-11-24

Primary completion

2021-09-16

Completion

2023-02-08

Publications

• Xue R, Wei M, Yuan J, Li Z, Zhou Y, Xue Z, Wu Y, Han H, Zhou J, Yu X, Shen L. A phase 1b/2 study of first-line anti-PD-L1/ TGF-betaRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma. Signal Transduct Target Ther. 2025 Dec 20;10(1):415. doi: 10.1038/s41392-025-02530-2.

Drugs

Indications